One of the more interesting areas of BPC-157 research involves gastrointestinal health
Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose
Smith The lawsuit argues that new federal rules went beyond what Congress enacted and broke from guidance that the federal government previewed to states
Int J Pharm 1999
A trained provider can properly assess your health, lifestyle, and wellness goals to create a personalized plan with the right dosage and schedule for you
In animal toxicology studies, no significant adverse effects have been observed even at doses far exceeding typical therapeutic ranges
